• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Akouos Inc. (Amendment)

    12/2/22 3:35:27 PM ET
    $AKUS
    Specialty Chemicals
    Consumer Discretionary
    Get the next $AKUS alert in real time by email
    SC 13D/A 1 tm2231848d1_sc13da.htm SC 13D/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT

    TO RULE 13d-2(a)

     

    (Amendment No. 2)*

     

      Akouos, Inc.  

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    00973J101

    (CUSIP Number)

     

    5AM Venture Management, LLC
    501 2nd Street, Suite 350
    San Francisco, CA 94107
    (415) 993-8565

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    November 30, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     

     

     

     

    CUSIP No. 12674W109 13D Page 2 of 11

     

    1.

    Name of Reporting Persons

     

    5AM Ventures V, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (see instructions)

     
      (a) ¨
      (b) x(1)
    3.

    SEC USE ONLY

     

    4.

    Source of Funds (see instructions)

     

    WC

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ¨
    6.

    Citizenship or Place of Organization 

     

    Delaware

     

    Number of

     

    Shares

     

    Beneficially

     

    Owned by

     

    Each

     

    Reporting

     

    Person With

    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power 

     

    0 shares of Common Stock

    9.

    Sole Dispositive Power 

     

    0

    10.

    Shared Dispositive Power 

     

    0 shares of Common Stock

     

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person 

     

    0 shares of Common Stock

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ¨
    13.

    Percent of Class Represented by Amount in Row 11

     

    0%

    14.

    Type of Reporting Person (see instructions)

     

    PN

     

    (1)This Schedule 13D is filed by 5AM Partners V, LLC (“5AM Partners V”), 5AM Ventures V, L.P. (“5AM V”), 5AM Opportunities I, L.P. (“5AM Opportunities”), 5AM Opportunities I (GP), LLC (“5AM Opportunities GP”), Andrew J. Schwab (“Schwab”), Dr. Kush Parmar (“Dr. Parmar”) and Dr. Scott M. Rocklage (“Dr. Rocklage” and, with 5AM Partners V, 5AM V, 5AM Opportunities, 5AM Opportunities GP, Schwab and Dr. Parmar, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

     

     

     

    CUSIP No. 12674W109 13D Page 3 of 11

     

    1.

    Name of Reporting Persons

     

    5AM Partners V, LLC

    2. Check the Appropriate Box if a Member of a Group (see instructions)  
      (a) ¨
      (b) x(1)
    3.

    SEC USE ONLY

     

    4.

    Source of Funds (see instructions)

     

    AF

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ¨
    6.

    Citizenship or Place of Organization

     

    Delaware

     

    Number of

     

    Shares

     

    Beneficially

     

    Owned by

     

    Each

     

    Reporting

     

    Person With

    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power 

     

    0 shares of Common Stock

    9.

    Sole Dispositive Power 

     

    0

    10.

    Shared Dispositive Power 

     

    0 shares of Common Stock

     

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person 

     

    0 shares of Common Stock

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ¨
    13.

    Percent of Class Represented by Amount in Row 11

     

    0%

    14.

    Type of Reporting Person (see instructions)

     

    OO

     

    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

     

     

     

    CUSIP No. 12674W109 13D Page 4 of 11

     

    1.

    Name of Reporting Persons  

     

    5AM Opportunities I, L.P.

    2. Check the Appropriate Box if a Member of a Group (see instructions)  
      (a) ¨
      (b) x(1)
    3.

    SEC USE ONLY

     

    4.

    Source of Funds (see instructions)

     

    WC

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ¨
    6.

    Citizenship or Place of Organization

     

    Delaware

    Number of

     

    Shares

     

    Beneficially

     

    Owned by

     

    Each

     

    Reporting

     

    Person With

    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power

     

    0 shares of Common Stock

    9.

    Sole Dispositive Power

     

    0

    10.

    Shared Dispositive Power

     

    0 shares of Common Stock

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person  

     

    0 shares of Common Stock

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ¨
    13.

    Percent of Class Represented by Amount in Row 11  

     

    0%

    14.

    Type of Reporting Person (see instructions)  

     

    PN

     

    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

     

     

     

    CUSIP No. 12674W109 13D Page 5 of 11

     

    1.

    Name of Reporting Persons  

     

    5AM Opportunities I (GP), LLC

    2. Check the Appropriate Box if a Member of a Group (see instructions)  
      (a) ¨
      (b) x(1)
    3.

    SEC USE ONLY

     

    4.

    Source of Funds (see instructions)

     

    AF

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ¨
    6. Citizenship or Place of Organization

    Delaware

    Number of

     

    Shares

     

    Beneficially

     

    Owned by

     

    Each

     

    Reporting

     

    Person With

    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power

     

    0 shares of Common Stock

    9.

    Sole Dispositive Power

     

    0

    10.

    Shared Dispositive Power

     

    0 shares of Common Stock

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person  

     

    0 shares of Common Stock

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ¨
    13.

    Percent of Class Represented by Amount in Row 11  

     

    0%

    14.

    Type of Reporting Person (see instructions)  

     

    OO

     

    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

     

     

     

    CUSIP No. 12674W109 13D Page 6 of 11

     

    1.

    Name of Reporting Persons  

     

    Dr. Kush Parmar

    2. Check the Appropriate Box if a Member of a Group (see instructions)  
      (a) ¨
      (b) x(1)
    3.

    SEC USE ONLY

     

    4.

    Source of Funds (see instructions)

     

    AF

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ¨
    6. Citizenship or Place of Organization

    United States

    Number of

     

    Shares

     

    Beneficially

     

    Owned by

     

    Each

     

    Reporting

     

    Person With

    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power

     

    0 shares of Common Stock

    9.

    Sole Dispositive Power

     

    0

    10.

    Shared Dispositive Power

     

    0 shares of Common Stock

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person  

     

    0 shares of Common Stock

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ¨
    13.

    Percent of Class Represented by Amount in Row 11  

     

    0%

    14.

    Type of Reporting Person (see instructions)  

     

    IN

     

    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

     

     

     

    CUSIP No. 12674W109 13D Page 7 of 11

     

    1.

    Name of Reporting Persons

     

    Andrew J. Schwab

    2. Check the Appropriate Box if a Member of a Group (see instructions)  
      (a) ¨
      (b) x(1)
    3.

    SEC USE ONLY

     

    4.

    Source of Funds (see instructions)

     

    AF

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ¨
    6.

    Citizenship or Place of Organization

     

    United States

    Number of

     

    Shares

     

    Beneficially

     

    Owned by

     

    Each

     

    Reporting

     

    Person With

    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power

     

    0 shares of Common Stock

    9.

    Sole Dispositive Power

     

    0

    10.

    Shared Dispositive Power

     

    0 shares of Common Stock

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0 shares of Common Stock

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ¨
    13.

    Percent of Class Represented by Amount in Row 11

     

    0%

    14.

    Type of Reporting Person (see instructions)

     

    IN

     

    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

     

     

     

    CUSIP No. 12674W109 13D Page 8 of 11

     

    1.

    Name of Reporting Persons

     

    Dr. Scott M. Rocklage

    2. Check the Appropriate Box if a Member of a Group (see instructions)  
      (a) ¨
      (b) x(1)
    3.

    SEC USE ONLY

     

    4.

    Source of Funds (see instructions)

     

    AF

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ¨
    6.

    Citizenship or Place of Organization

     

    United States

    Number of

     

    Shares

     

    Beneficially

     

    Owned by

     

    Each

     

    Reporting

     

    Person With

    7.

    Sole Voting Power

     

    0

    8.

    Shared Voting Power

     

    0 shares of Common Stock

    9.

    Sole Dispositive Power

     

    0

    10.

    Shared Dispositive Power

     

    0 shares of Common Stock

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0 shares of Common Stock

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ¨
    13.

    Percent of Class Represented by Amount in Row 11

     

    0%

    14.

    Type of Reporting Person (see instructions)

     

    IN

     

    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

     

     

     

    CUSIP No. 12674W109 13D Page 9 of 11

     

    Explanatory Note: This Amendment No. 2 (the “Amendment”), which amends the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on July 10, 2020 and amended on December 31, 2020 (the “Original Schedule 13D”) is being filed on behalf of 5AM Partners V, LLC (“5AM Partners V”), 5AM Ventures V, L.P. (“5AM V”), 5AM Opportunities I, L.P. (“5AM Opportunities”), 5AM Opportunities I (GP), LLC (“5AM Opportunities GP”), Andrew J. Schwab (“Schwab”), Dr. Kush Parmar (“Dr. Parmar”) and Dr. Scott M. Rocklage (“Dr. Rocklage” and, with 5AM Partners V, 5AM V, 5AM Opportunities, 5AM Opportunities GP, Schwab and Dr. Parmar, collectively, the “Reporting Persons”) in respect of the Common Stock, $0.0001 par value per share (“Common Stock”), of Akouos, Inc., a Delaware corporation (the “Issuer” or “Akouos”). This Amendment is being filed for the purpose of reporting the disposition of the securities of the Issuer by the Reporting Persons in connection with the closing of the Merger (as defined below). The Original Schedule 13D is hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D.

     

    Item 4.Purpose of Transaction

     

    Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following paragraph at the end of Item 4:

     

    Pursuant to an Agreement and Plan of Merger, dated as of October 17, 2022 (the “Merger Agreement”), by and among the Issuer, Eli Lilly and Company, an Indiana corporation (“Parent”), and Parent’s wholly owned subsidiary, Kearny Acquisition Corporation (“Merger Sub”), prior to the Expiration Date (as defined in the Merger Agreement), each of 5AM V and 5AM Opportunities tendered all of its respective shares of Common Stock of the Issuer (the “Shares”) in the tender offer contemplated by the Merger Agreement. On November 30, 2022, these Shares were accepted in the tender offer at the Acceptance Time (as defined in the Merger Agreement) in exchange for (i) $12.50 per Share, net to the stockholder in cash, without interest (the “Cash Consideration”) and less any applicable tax withholding, plus (ii) one non-tradable contingent value right (“CVR”) per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A.

     

    Pursuant to the terms of the Merger Agreement, each outstanding option with an exercise price equal to or greater than $12.50 per Share became exercisable on November 23, 2022 up to and through the close of regular trading on the Nasdaq Global Select Market on November 28, 2022. Dr. Parmar did not elect to exercise his option. On December 1, 2022, at the effective time of the merger (the “Merger”) contemplated by the Merger Agreement (the “Effective Time”), pursuant to the Merger Agreement, each outstanding and unexercised option with an exercise price equal to or greater than $12.50 per Share was terminated without any consideration in respect of such cancelled option.

     

    On December 1, 2022, at the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by (B) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option and (y) one CVR for each Share subject to such option immediately prior to the Effective Time (without regard to vesting).

     

     

     

     

    CUSIP No. 12674W109 13D Page 10 of 11

     

    Item 5.Interest in Securities of the Issuer

     

    Item 5 of the Original Schedule 13D is hereby amended and restated in its entirety as follows:

     

    (a) – (b). The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13D is provided as of December 1, 2022:

     

    Reporting Persons  Shares
    Held
    Directly
       Sole
    Voting
    Power
       Shared
    Voting
    Power
       Sole
    Dispositive
    Power
       Shared
    Dispositive
    Power
       Beneficial
    Ownership
       Percentage
    of Class
     
    5AM V  0   0   0   0   0   0   0%
    5AM Partners V  0   0   0   0   0   0   0%
    5AM Opportunities  0   0   0   0   0   0   0%
    5AM Opportunities GP  0   0   0   0   0   0   0%
    Dr. Parmar  0   0   0   0   0   0   0%
    Schwab  0   0   0   0   0   0   0%
    Dr. Rocklage  0   0   0   0   0   0   0%

     

    (c)Except as set forth herein, none of the Reporting Persons has effected any transactions in shares of the Issuer’s Common Stock during the last 60 days.

     

    (d)No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons.

     

    (e)The Reporting Persons ceased to be the beneficial owners of more than five percent of the Common Stock on November 30, 2022.

     

     

     

     

    CUSIP No. 12674W109 13D Page 11 of 11

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date:  December 2, 2022

     

    5AM VENTURES V, L.P.  
       
    By: 5AM Partners V, LLC,  
      its General Partner  
       
    By: /s/ Scott M. Rocklage  
      Dr. Scott M. Rocklage  
      Managing Member  
       
    5AM PARTNERS V, LLC  
       
    By: /s/ Scott M. Rocklage  
      Dr. Scott M. Rocklage  
      Managing Member  
       
    5AM OPPORTUNITIES I, L.P.  
       
    By: 5AM Opportunities I (GP), LLC,  
      its General Partner  
       
    By: /s/ Kush Parmar  
      Dr. Kush Parmar  
      Managing Member  
       
    5AM Opportunities I (GP), LLC  
       
    By: /s/ Kush Parmar  
      Dr. Kush Parmar  
      Managing Member  
       
    /s/ Kush Parmar  
    Dr. Kush Parmar  
       
    /s/ Scott M. Rocklage  
    Dr. Scott Rocklage  
       
    /s/ Andrew J. Schwab  
    Andrew J. Schwab  

     

     

    Get the next $AKUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKUS

    DatePrice TargetRatingAnalyst
    9/29/2022$12.00Outperform
    William Blair
    More analyst ratings

    $AKUS
    Leadership Updates

    Live Leadership Updates

    See more
    • Akouos Appoints Aaron Tward, M.D., Ph.D., as Chief Scientific Officer

      BOSTON, March 10, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Aaron Tward, M.D., Ph.D., as chief scientific officer. Dr. Tward is a surgeon and a scientist with deep experience in genetics, genomics, gene delivery, high-throughput sequencing technologies, and the clinical care of patients with conditions of the ear and skull base. Dr. Tward was previously a member of the Akouos scientific advisory board since 2018. As chief scientific officer, he will lead the research team, and provide strategic scie

      3/10/22 7:00:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • Akouos Appoints Stacy Price as Chief Technical Officer

      BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Stacy Price as chief technical officer. Ms. Price brings to Akouos more than 25 years of experience managing clinical and commercial biotechnology manufacturing and technical operations for a wide range of therapeutic modalities, including gene therapy. At Akouos, she will be responsible for the strategy and operations of vector development and manufacturing, as well as device development and engineering. "We are excited to welcome Stacy to

      11/1/21 7:00:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • Akouos Appoints Dr. Kathy Reape as Chief Development Officer

      BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Dr. Kathy Reape as chief development officer. Dr. Reape brings over 20 years of experience in the pharmaceutical industry, including significant gene therapy translational and development expertise, to Akouos. "We welcome Dr. Reape to the Akouos team at this exciting time in the company's growth, as we continue to advance the AK-OTOF and AK-antiVEGF programs towards our planned IND submissions in 2022," said Manny Simons, Ph.D., M.B.A., co-f

      5/7/21 7:00:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary

    $AKUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Walker Paul Edward (tax withholding)

      4 - Akouos, Inc. (0001722271) (Issuer)

      12/2/22 5:13:26 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Sonsini Peter W. (tax withholding)

      4 - Akouos, Inc. (0001722271) (Issuer)

      12/2/22 5:12:13 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Sandell Scott D to satisfy withholding tax

      4 - Akouos, Inc. (0001722271) (Issuer)

      12/2/22 5:10:58 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary

    $AKUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Akouos with a new price target

      William Blair initiated coverage of Akouos with a rating of Outperform and set a new price target of $12.00

      9/29/22 9:08:33 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • HC Wainwright & Co. initiated coverage on Akouos with a new price target

      HC Wainwright & Co. initiated coverage of Akouos with a rating of Buy and set a new price target of $25.00

      4/27/21 6:28:58 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • Akouos downgraded by BofA Securities with a new price target

      BofA Securities downgraded Akouos from Buy to Neutral and set a new price target of $20.00 from $24.00 previously

      3/30/21 6:33:57 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary

    $AKUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Akouos Inc. (Amendment)

      SC 13G/A - Akouos, Inc. (0001722271) (Subject)

      2/14/23 3:32:27 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Akouos Inc. (Amendment)

      SC 13G/A - Akouos, Inc. (0001722271) (Subject)

      2/10/23 1:59:31 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Akouos Inc. (Amendment)

      SC 13G/A - Akouos, Inc. (0001722271) (Subject)

      1/10/23 12:48:26 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary

    $AKUS
    Financials

    Live finance-specific insights

    See more
    • Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights

      -Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial -Continued progress toward planned IND submission for AK-antiVEGF in 2023 -Announced on October 18 definitive agreement for Eli Lilly and Company to acquire Akouos BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the third quarter ended September 30, 2022 and provides business highlights. "This has been a transformative year for us, and we've achieved

      11/14/22 7:15:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • Akouos Reports Second Quarter 2022 Financial Results and Provides Business Highlights

      Submitted IND for AK-OTOF to FDA Continued progress toward planned IND submission for AK-antiVEGF Presented new nonclinical data at ASGCT supporting the proposed clinical development of AK-OTOF and highlighting strategies for regulated gene expression in the inner ear Received a notice of allowance from USPTO for claims covering compositions, including AK-OTOF, and methods of treatment useful for OTOF-mediated hearing lossEnded Q2 2022 with a strong cash position of $192.9 million BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing los

      8/15/22 7:00:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • Akouos Reports First Quarter 2022 Financial Results and Provides Business Highlights

      - Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Presenting new nonclinical data at ASGCT supporting the planned clinical development of AK-OTOF and highlighting the potential use of microRNA target sites in AAV vectors for regulated gene expression in the inner ear - Presented new nonclinical data at ARO demonstrating potential of precision genetic medicine platform to address a broad range of inner ear conditions -Ended the first quarter with a strong cash position of $209.1 million BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potenti

      5/12/22 7:45:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary

    $AKUS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases

      INDIANAPOLIS, Dec. 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ:AKUS). The acquisition expands Lilly's efforts in genetic medicines to include Akouos's portfolio of potential first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss. "Akouos brings more top-tier talent and an important pipeline to Lilly's Institute for Genetic Medicine that will further accelerate our work to advance genetic medicines for people living with difficult-to-treat diseases," said Andrew C. Adams, Ph.D., senior vice president of genetic medicine

      12/1/22 8:41:00 AM ET
      $AKUS
      $LLY
      Specialty Chemicals
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly and Akouos Announce Expiration of Akouos Tender Offer

      INDIANAPOLIS and BOSTON, Nov. 30, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Akouos, Inc. (NASDAQ:AKUS) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Akouos's common stock in exchange for (a) $12.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones (the "Offer"), expire

      11/30/22 6:50:00 AM ET
      $AKUS
      $LLY
      Specialty Chemicals
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights

      -Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial -Continued progress toward planned IND submission for AK-antiVEGF in 2023 -Announced on October 18 definitive agreement for Eli Lilly and Company to acquire Akouos BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the third quarter ended September 30, 2022 and provides business highlights. "This has been a transformative year for us, and we've achieved

      11/14/22 7:15:00 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary

    $AKUS
    SEC Filings

    See more
    • SEC Form 15-12G filed by Akouos Inc.

      15-12G - Akouos, Inc. (0001722271) (Filer)

      12/12/22 4:11:07 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form EFFECT filed by Akouos Inc.

      EFFECT - Akouos, Inc. (0001722271) (Filer)

      12/6/22 12:15:08 AM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form POS AM filed by Akouos Inc.

      POS AM - Akouos, Inc. (0001722271) (Filer)

      12/1/22 4:42:00 PM ET
      $AKUS
      Specialty Chemicals
      Consumer Discretionary